KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Free Cash Flow data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 174.43% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.3 billion, down 7.08%, while the annual FY2025 figure was $1.3 billion, 7.08% down from the prior year.
  • Free Cash Flow reached $1.2 billion in Q4 2025 per JAZZ's latest filing, up from -$356.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.2 billion in Q4 2025 and bottomed at -$356.6 million in Q3 2025.
  • Average Free Cash Flow over 5 years is $287.7 million, with a median of $290.9 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 742.36% in 2022, then tumbled 195.35% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $167.8 million in 2021, then soared by 98.22% to $332.6 million in 2022, then tumbled by 52.72% to $157.2 million in 2023, then surged by 169.25% to $423.4 million in 2024, then skyrocketed by 174.43% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $1.2 billion in Q4 2025, -$356.6 million in Q3 2025, and $75.9 million in Q2 2025.